多发性骨髓瘤的序贯靶向治疗:GPRC5D 双特异性抗体 talquetamab 作为 BCMA CAR-T 治疗的桥接 Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. PubMed 2025/10/23 发表BloodQ1 · IF 23.9(JCR 2025) 靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体急性髓系白血病多发性骨髓瘤